Cardio Diagnostics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Cardio Diagnostics Holdings (NASDAQ:CDIO) Full Year 2023 Results
Key Financial Results
Net loss: US$8.38m (loss widened by 80% from FY 2022).
US$0.66 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cardio Diagnostics Holdings EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 88%. Earnings per share (EPS) exceeded analyst estimates by 15%.
Looking ahead, revenue is forecast to grow 111% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 24% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 6 warning signs for Cardio Diagnostics Holdings you should be aware of, and 4 of them can't be ignored.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.